Results 101 to 110 of about 22,676 (187)

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 891-904, April 2026.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source

Twenty Years of Therapeutic Leukocytapheresis in Newly Diagnosed Acute Myeloid Leukemia: Insights From A Single Center

Journal of Clinical Apheresis, Volume 41, Issue 2, April 2026.
ABSTRACT Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, and 5%–20% of newly diagnosed patients present with hyperleukocytosis (HL). HL, most often defined as WBC > 100 000/μL, is a hematologic emergency associated with severe complications, early mortality, and poor prognosis, requiring immediate intervention.
Vojtech Latal, Ivana Skoumalova, Miroslava Palova, Tomas Szotkowski, Martin Cernan, Jana Navratilova, Helena Urbankova, Zuzana Pikalova, Ludek Raida, Edgar Faber, Tomas Papajik   +10 more
wiley   +1 more source

Real‐World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Venetoclax plus azacitidine (V+A) is standard for older, intensive‐ineligible patients with acute myeloid leukemia (AML). Its expanding use in younger, curative‐eligible adults lacks comparative evidence against conventional 7+3 induction, raising uncertainty about potential survival compromise.
Nehemias Guevara Rodriguez, Noemy Coreas Mercado, Syeda Ashna Fatima Kamal, Sandeep Beesabathina, Dawson Foster, Nabeel Rajeh, Ranju Kunwor   +6 more
wiley   +1 more source

Giant cellulitis‐like Sweet's syndrome induced by gilteritinib

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Juan de Luque‐Fernández, Irene Rivera‐Ruiz, Irene Suárez‐Vergne, Inmaculada Sánchez‐Ramírez, Manuel Galán‐Gutiérrez, Antonio José Vélez García‐Nieto   +5 more
wiley   +1 more source

Identification of an Elusive CBFA2T3::GLIS2 Fusion Variant in Acute Megakaryoblastic Leukemia by Whole Genome Sequencing

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Advancements in genomic profiling have significantly improved the classification and treatment strategies for acute myeloid leukemia (AML). However, widely utilized molecular diagnostic techniques, including targeted gene panels, are often insufficient for detecting complex structural variants, cryptic fusions, and poorly characterized driver ...
Yuna Lee, Jung Yoon Choi, Hyun Jin Park, Bo Kyung Kim, Hyun Kyung Kim, Yeseul Kim, Jung‐Eun Cheon, Sung‐Hye Park, Ji Hoon Phi, Ji Won Lee, Ryul Kim, June‐Young Koh, Hyoung Jin Kang   +12 more
wiley   +1 more source

Integrating Gene Expression With Recurrent Mutations Improves Age‐Stratified Risk Prediction in Acute Myeloid Leukemia

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Older adults with acute myeloid leukemia (AML) have inferior outcomes, yet current genetic risk models do not explicitly account for how age modifies the prognostic impact of molecular features. We hypothesized that integrating apoptosis and p53‐related gene expression with recurrent mutations would improve prediction of complete ...
Mobina Shrestha, Salina Dahal, Asis Shrestha, Patricia McNally, Amir Babu Shrestha, Niklas Mackler   +5 more
wiley   +1 more source

Improvements in Real‐World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment

European Journal of Haematology, Volume 116, Issue 4, Page 416-424, April 2026.
ABSTRACT Therapeutic options for newly diagnosed (ND) acute myeloid leukemia (AML) have increased in recent years, leading to a shift in the treatment paradigm from conventional, intensive chemotherapy toward targeted and less intensive therapy. Since 2017, there has been a surge in FDA approvals for novel therapies, including small molecule inhibitors
Thuy N. Ho, Patrick Willard, Graeme F. Murray, Li Liu, Nolan Wages, Hyun Lee, Keri R. Maher   +6 more
wiley   +1 more source

Distinct Pattern of Atypical Megakaryocytes in VEXAS Syndrome

International Journal of Laboratory Hematology, EarlyView.
Andrew Y. Sung, Jackson W. Douglas, Olga K. Weinberg, Sharon K. Germans, Weina Chen   +4 more
wiley   +1 more source

Efficacy and Safety of Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients

European Journal of Haematology, Volume 116, Issue 4, Page 443-449, April 2026.
ABSTRACT This retrospective study evaluates the efficacy and safety of donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT) in children. We describe the long‐term use of preemptive, prophylactic, and therapeutic DLI with a gradual dose increase in half‐log increments.
Dinah Walther, Jana Ernst, Carola Wollenhaupt, Susan Wittig, Manuela Härtel, Grit Brodt, Till Milde, Bernd Gruhn   +7 more
wiley   +1 more source

Successful remission induction therapy with azacitidine and venetoclax for a treatment-naive elderly patient with ETP/myeloid mixed-phenotype acute leukemia: a case report

Frontiers in Oncology
BackgroundMixed-phenotype acute leukemia (MPAL) is a rare acute leukemia for which data are currently not available to guide therapy. It has a poor outcome, particularly in elderly patients.Case presentationWe report the successful use of venetoclax ...
Kaikai Huang, Yanbin Pang
doaj   +1 more source